Aidoc
Aidoc is a leading artificial intelligence company focused on advancing clinical imaging and workflow orchestration for large health systems. Its enterprise-grade platform, aiOS, is designed to seamlessly integrate and scale AI solutions across a hospital’s imaging and IT infrastructure. Aidoc’s core function is to analyze medical images around the clock, leveraging a foundation model-powered platform to triage acute conditions and orchestrate care by meeting radiologists where they work, inside PACS, reporting tools, and the Electronic Health Record (EHR). The platform includes its own suite of FDA-cleared AI algorithms and integrates third-party tools, enabling health systems to consolidate multiple AI algorithms onto a single operating system. By automatically detecting time-sensitive conditions and prioritizing high-risk cases based on clinical urgency, Aidoc significantly reduces delays in diagnosis and treatment, ultimately leading to faster and more efficient patient care.
Latest Market Research Report on Artificial Intelligence in Healthcare Download PDF Brochure Now
DeepScribe
DeepScribe utilizes ambient AI to tackle the significant challenge of clinician burnout caused by extensive administrative work, focusing on transforming natural patient-physician conversations into comprehensive medical documentation. Its platform listens in the exam room using ambient voice technology and natural language processing to write structured, accurate clinical notes, freeing physicians to focus entirely on patient care. The proprietary HealAI-powered platform provides end-to-end clinical documentation, including on-the-fly suggestions for coding (ICD-10, HCC, and E/M) and quality cues. DeepScribe boasts deep integrations with major Electronic Health Record (EHR) systems like Epic (SmartData) and athenahealth. Having achieved a 98.8 KLAS score and demonstrated the ability to reduce documentation time by approximately 75% for its users, the company has established itself as a key player in the AI-powered clinical documentation market, ideal for large health systems and specialty groups seeking operational efficiency.
Suki
Suki is a major provider of an AI Assistant that employs medically tuned Large Language Models (LLMs) and best-in-class speech recognition to streamline clinical workflows and alleviate the administrative burden on clinicians. The core function of the Suki Assistant is to generate ambient clinical notes automatically from patient encounters, allowing doctors to speak naturally about the visit without interrupting the flow of conversation or patient interaction. Beyond ambient documentation, Suki supports clinicians with voice commands, coding assistance, and pre-charting features. The platform is designed to integrate deeply and bidirectionally with major EHRs, including Epic, Oracle Health, athenahealth, and MEDITECH, ensuring data synchronization and a seamless user experience. By automating the paperwork and handling administrative tasks, Suki aims to significantly improve clinician work-life satisfaction, making complex medical analysis faster, more scalable, and ultimately allowing physicians to reclaim valuable time for patient care.
PathAI
PathAI is a technological leader in digital pathology, dedicated to improving patient outcomes through the application of artificial intelligence for diagnosing and treating disease, primarily cancer. The company develops and deploys advanced machine learning algorithms to analyze pathology images, aiming to increase the speed and accuracy of diagnostics. Its flagship AISight platform received FDA clearance to be used for actual diagnoses, marking a significant advancement in the field. PathAI’s technology provides critical support to pathologists by identifying subtle biomarker signatures and integrating molecular data, helping to overcome challenges like the shortage of pathologists and the complexity of modern oncology. By digitizing and analyzing pathology images with AI, PathAI empowers pharmaceutical companies with better data for drug discovery and helps clinicians personalize treatment plans, solidifying its role as a pivotal force in the future of precision medicine.
Cleerly
Cleerly is at the forefront of using AI to revolutionize the detection and understanding of cardiovascular disease. The company specializes in non-invasive, quantitative analysis of coronary computed tomography angiography (CCTA) studies using FDA-cleared machine learning algorithms. Cleerly’s technology moves beyond traditional stenosis assessment to provide a comprehensive, detailed picture of atherosclerosis by measuring, quantifying, and categorizing coronary plaque build-up. Its AI generates a 3D model of the patient’s coronary arteries, allowing healthcare providers to assess the likelihood of ischemia and predict potential heart issues. This level of personalized, quantitative data enables a shift from reactive care to proactive, preventative medicine, allowing for tailored treatment plans that target the specific type and amount of plaque, thereby enhancing diagnostic certainty and ultimately improving patient outcomes related to heart health.
Tempus
Tempus is a global technology company focused on providing a sophisticated, AI-assisted approach to personalized cancer treatment and drug discovery by analyzing massive amounts of clinical and molecular data. The company’s platform works by sequencing the unique tumor genetics of each patient, combining this with a vast library of real-world clinical data. Its machine learning models then assist doctors in selecting the most effective treatment protocols, essentially providing a dedicated research team for every patient. Tempus accelerates therapeutic analysis and evidence generation by unifying and structuring clinical, operational, and financial data across healthcare organizations. This data-driven approach allows for the discovery of new insights, the selection of optimal therapies, and the acceleration of research programs, thereby making complex genetic analysis actionable and advancing the goal of precision medicine on a large scale.
Medtronic
Medtronic, one of the world’s largest medical device manufacturers, is strategically integrating artificial intelligence into its core product portfolio to improve patient health outcomes across various therapeutic areas, including surgical robotics, cardiovascular solutions, and diabetes care. The company designs, develops, and deploys AI-enabled technologies that enhance the precision and effectiveness of medical procedures and ongoing care. A notable example is the GI Genius intelligent endoscopy module, an AI-based system that uses deep learning to scan every visual frame during a colonoscopy in real-time. This system alerts physicians to the presence of colorectal polyps, especially those that are small or flat and may be easily missed by the human eye. By embedding AI directly into its devices, Medtronic provides clinicians with powerful, real-time decision support, helping to increase detection rates and ultimately enabling more effective, timely interventions for critical health conditions.
Owkin
Owkin is a French-American biopharma company that specializes in applying machine learning and deep learning to massive, multimodal medical datasets to accelerate drug discovery and the development of new therapies. The company is built on the principle of federated learning, which allows its AI models to be trained on data from multiple institutions without the need for the data to be physically pooled or moved, thus protecting patient privacy. Owkin’s AI models analyze complex biological information to uncover novel insights, identify new drug targets, and better understand disease mechanisms. By linking patient clinical and molecular data, Owkin helps pharmaceutical companies and researchers streamline the R&D pipeline, making the journey to discovery in precision medicine faster and more capital efficient. This approach is instrumental in advancing research for conditions like cancer and infectious diseases.
Google Health/DeepMind
Google Health, which includes the former DeepMind health team, is a key technology giant that leverages its core AI and data processing capabilities to drive transformative change in healthcare. The company’s AI models have demonstrated groundbreaking potential in diagnostics, notably by outperforming human radiologists in identifying breast cancer from mammograms and aiding in the detection of lung cancer. Google Health is actively involved in developing AI-driven solutions for predicting patient outcomes, creating personalized treatment plans, and analyzing complex biological data to accelerate drug discovery. Furthermore, Google Cloud provides the robust and secure infrastructure for healthcare organizations to store, standardize, and apply machine learning to vast clinical datasets, facilitating better care coordination and operational planning. Through these diverse initiatives, Google is focused on improving patient outcomes, empowering clinicians, and optimizing the operational efficiency of the healthcare sector globally.
NVIDIA
NVIDIA is not a direct healthcare service provider but plays an indispensable, foundational role in powering AI innovation across the medical sector by providing the computational infrastructure necessary for complex AI workloads. The company’s industry-leading Graphics Processing Units (GPUs) are the engine for training and deploying sophisticated AI models used in medical imaging, genomics, and drug discovery. NVIDIA’s Clara platform is an integrated software and hardware suite specifically designed for healthcare AI, offering a comprehensive application framework that accelerates development in areas like biopharma, medical devices, and medical imaging. By providing researchers and healthcare enterprises with high-performance computing systems, NVIDIA enables them to build and deploy performance-intensive AI models with the speed and scale required for clinical environments, thus acting as the essential technological backbone for next-generation healthcare breakthroughs.
Viz.ai
Viz.ai is a leading AI company that focuses on accelerating treatment and synchronizing care for time-sensitive medical conditions, with a primary emphasis on neurovascular and vascular care. Its core offering is the Viz One care coordination platform, which leverages over 50 FDA-cleared AI algorithms to automatically detect suspected diseases from various imaging sources like CT, echo, and EKG. The platform is designed to ingest imaging data directly from the scanner and instantly run relevant algorithms. Once a critical finding is detected, Viz.ai’s system immediately sends configurable alerts and secure team messaging to the relevant care team members. By connecting specialists and coordinating patient management through intelligent automation, Viz.ai drastically reduces the time to treatment for conditions like stroke, demonstrating a significant impact on clinical efficiency and the potential for life-saving patient outcomes.
TeleVox
TeleVox specializes in patient engagement and communication, leveraging conversational AI to automate and enhance interactions between healthcare providers and patients. The company’s AI-powered solutions, such as the SMART Agent, serve as an inbound interactive virtual agent that can instantly answer patient calls 24/7 to handle routine tasks, including appointment scheduling, checking billing information, and processing prescription refill requests. For outbound communication, the platform uses AI to send automated, smarter reminders and follow-ups, which is a proven method for significantly reducing patient no-show rates. By integrating its conversational AI across text, email, phone, and web chat channels, TeleVox helps healthcare organizations streamline their front-line operations, improve scheduling efficiency, and enhance the overall patient experience, thereby allowing staff to focus on higher-value tasks and improving the financial health of the practice.
Latest Market Research Report on Artificial Intelligence in Healthcare Download PDF Brochure Now